专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20120322821A1 GHRELIN RECEPTOR AGONIST FOR TREATMENT OF CACHEXIA 审中-公开
标题翻译： GHRELIN受体激动剂治疗慢性乙型肝炎
公开(公告)号：US20120322821A1
公开(公告)日：2012-12-20
申请号：US13580479
申请日：2011-02-28
申请人： Kaoru Shimada , Masaki Sudo , Masaomi Tajimi , Nobuyuki Takahashi , Kazuhiko Nonomura
发明人： Kaoru Shimada , Masaki Sudo , Masaomi Tajimi , Nobuyuki Takahashi , Kazuhiko Nonomura
IPC分类号： A61K31/437 , A61P3/00 , C07D471/04
CPC分类号： C07D471/04 , A61K31/437 , A61K45/06
摘要： The present invention relates to use of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, for the manufacture of a medicament for the treatment of cachexia. The invention also relates to a method for the treatment of cachexia, comprising administering the compound of the present invention or a pharmaceutical composition comprising the same to a human or an animal. The invention further relates to use of said compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, in combination with one or more second active agents. Moreover, the invention relates to a pharmaceutical composition and a kit comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, for the treatment of said disease.
摘要翻译：本发明涉及本发明化合物或其药学上可接受的盐或包含该化合物或其盐的药物组合物在制备用于治疗恶病质的药物中的用途。本发明还涉及治疗恶病质的方法，其包括向人或动物施用本发明化合物或其包含该化合物的药物组合物。本发明还涉及所述化合物或其药学上可接受的盐或包含该化合物或盐的药物组合物与一种或多种第二活性剂的组合的用途。此外，本发明涉及药物组合物和包含本发明化合物或其药学上可接受的盐的试剂盒，用于治疗所述疾病。

22. 发明授权

US07723321B2 Chromane substituted benzimidazole derivatives 有权
标题翻译：苯并二氢苯并咪唑衍生物
公开(公告)号：US07723321B2
公开(公告)日：2010-05-25
申请号：US11612583
申请日：2006-12-19
申请人： Takeshi Hanazawa , Hiroki Koike
发明人： Takeshi Hanazawa , Hiroki Koike
IPC分类号： A61K31/4184 , C07D405/02 , C07D407/02
CPC分类号： C07D405/12 , C07D409/12
摘要： This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, B, X, R1, R2, R3, R4, R5, R6, R7 and R8 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.
摘要翻译：本发明涉及式（I）化合物或其药学上可接受的盐，其中：A，B，X，R 1，R 2，R 3，R 4，R 5，R 6，R 7和R 8各自如本文所述，可接受的盐和含有这些化合物的组合物，以及这些化合物在治疗由酸泵拮抗活性（例如但不限于胃肠疾病，胃食管疾病，胃食管反流病（GERD）），消化性溃疡，胃溃疡，十二指肠溃疡，NSAID诱发的溃疡，胃炎，幽门螺杆菌感染，消化不良，功能性消化不良，佐林格 - 埃利森综合征，非侵蚀性反流病（NERD），内脏痛，胃灼热，恶心，食管炎，吞咽困难，过度激素，气道障碍或哮喘。

23. 发明授权

US07718809B2 Chromane substituted benzimidazole derivatives as acid pump antagonists 有权
标题翻译：色烷取代的苯并咪唑衍生物作为酸泵拮抗剂
公开(公告)号：US07718809B2
公开(公告)日：2010-05-18
申请号：US11916671
申请日：2006-06-02
申请人： Hiroki Koike , Sachiko Sakakibara
发明人： Hiroki Koike , Sachiko Sakakibara
IPC分类号： A61K31/4184 , C07D405/12
CPC分类号： C07D405/12 , C07D405/14
摘要： This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, B, X, R1, R2, R3, R4, R5 and R6, R7, R8 and R9 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.
摘要翻译：本发明涉及式（I）化合物或其药学上可接受的盐，其中：A，B，X，R 1，R 2，R 3，R 4，R 5和R 6，R 7，R 8和R 9各自如本文所述或药学上可接受的盐，以及含有这些化合物的组合物，以及这些化合物在治疗由酸泵拮抗活性介导的病症中的用途，例如但不限于胃肠道疾病，胃食管疾病，胃食管反流病（GERD），消化性溃疡，胃溃疡，十二指肠溃疡，NSAID诱导的溃疡，胃炎，幽门螺杆菌感染，消化不良，功能性消化不良，佐林格 - 埃里森综合征，非侵蚀性反流疾病（NERD），内脏痛，胃灼热，恶心，食管炎，吞咽困难，过度激活，气道障碍或哮喘。

24. 发明申请

US20210379158A1 METHOD FOR PREVENTING OR TREATING HEART FAILURE BY ADMINISTERING A MEDICAMENT CONTAINING AN ANTAGONIST OF CORTICOTROPIN RELEASING HORMONE RECEPTOR 2 (CRHR2) 有权
公开(公告)号：US20210379158A1
公开(公告)日：2021-12-09
申请号：US17404223
申请日：2021-08-17
申请人： RaQualia Pharma Inc.
发明人： Mikito TAKEFUJI
IPC分类号： A61K38/22 , G01N33/74 , A61P9/04 , A61K31/167 , A61K38/16
摘要： A medicament for preventing or treating heart failure containing an antagonist of the corticotropin releasing hormone receptor 2 as an active ingredient.

25. 发明申请

US20210085667A1 TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS 有权
公开(公告)号：US20210085667A1
公开(公告)日：2021-03-25
申请号：US17112097
申请日：2020-12-04
申请人： RaQualia Pharma Inc. , Asahi Kasei Pharma Corporation
发明人： Hirohide NOGUCHI , Yoshimasa ARANO , Kazuo ANDO , Kazuki TOYOSHIMA , Toshihiko SONE , Koki MATSUBARA
IPC分类号： A61K31/47 , C07D215/06
摘要： The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.

26. 发明申请

US20180338954A1 USES OF BENZIMIDAZOLE DERIVATIVE FOR NOCTURNAL ACID BREAKTHROUGH 审中-公开
公开(公告)号：US20180338954A1
公开(公告)日：2018-11-29
申请号：US15580850
申请日：2016-06-08
申请人： CJ HEALTHCARE CORPORATION
发明人： Ha Jin LEE , Bong Tae KIM , Hyun KIM , Ji Yeon NAM , Jie Eun PARK , Geun Seog SONG , Shin Young RYU , Shinichi KOIZUMI , Nobuyuki TAKAHASHI , Masaomi TAJIMI
IPC分类号： A61K31/4184 , A61P1/04 , A61K9/28
CPC分类号： A61K31/4184 , A61K9/20 , A61K9/28 , A61P1/04
摘要： The present invention relates to a use of benzimidazole derivative compounds for improvement and treatment of nocturnal acid breakthrough (NAB). The benzimidazole derivative compounds can mere effectively prevent and treat gastric acid-related diseases by effectively improving and treating nocturnal nocturnal acid breakthrough symptoms.

27. 发明授权

US09988370B2 Benzisoxazole derivative salt 有权
公开(公告)号：US09988370B2
公开(公告)日：2018-06-05
申请号：US15312440
申请日：2015-05-20
申请人： RaQualia Pharma Inc.
发明人： Toyoharu Numata , Masaki Sudo , Xufeng Sun
IPC分类号： C07D413/14 , A61K31/454
CPC分类号： C07D413/14 , A61K31/454
摘要： Salts of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid are disclosed. More particularly, salt forms (HCl-salt, HBr-salt, p-toluenesulfonate salt and ethanedisulfonate salt) are disclosed. Furthermore, processes for the preparation of such salt forms, compositions containing such salt forms, and uses of such salt forms are disclosed. A method of treating disease conditions mediated by 5-HT4 receptor activity includes administering an effective amount of such salt forms to an animal, including a human, in need of such treatment.

28. 发明授权

US09944634B2 Pyrazolopyridine derivatives as TTX-S blockers 有权
公开(公告)号：US09944634B2
公开(公告)日：2018-04-17
申请号：US14434203
申请日：2013-10-31
申请人： RaQualia Pharma Inc.
发明人： Kiyoshi Kawamura , Tatsuya Yamagishi , Yoshimasa Arano , Mikio Morita
IPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/5377
CPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/5377
摘要： The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

29. 发明授权

US09873695B2 Serine derivatives as ghrelin receptor agonists 有权
公开(公告)号：US09873695B2
公开(公告)日：2018-01-23
申请号：US15316543
申请日：2015-08-05
申请人： RaQualia Pharma Inc.
发明人： Yasuhiro Iwata , Kiyoshi Kawamura , Masaki Sudo , Kaoru Shimada , Shinichi Koizumi , Nobuyuki Takahashi , Keiko Obata , Makiko Kuroda
IPC分类号： C07D401/14 , A61K31/437 , C07D471/04 , C07K5/062 , G01N33/68
CPC分类号： C07D471/04 , A61K31/437 , C07K5/06034 , G01N33/6893 , G01N2333/575
摘要： The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.

30. 发明授权

US09447065B2 Pharmaceutical composition 有权
标题翻译：药物组成
公开(公告)号：US09447065B2
公开(公告)日：2016-09-20
申请号：US14351190
申请日：2012-10-18
申请人： RaQualia Pharma Inc.
发明人： Yasuhiro Iwata , Kaoru Shimada , Yoshiyuki Okumura , Mayumi Kashino , Hiromitsu Yoshida
IPC分类号： A61K31/352 , C07D311/58 , A61K9/16 , A61K9/20 , A61K47/48 , C08B37/16 , C08L5/16 , B82Y5/00
CPC分类号： C07D311/58 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K9/2013 , A61K9/2018 , A61K9/205 , A61K9/2054 , A61K31/352 , A61K47/6951 , B82Y5/00 , C08B37/0015 , C08L5/16
摘要： The present invention provides a pharmaceutical composition which prevents from decreasing the blood exposure of the third generation coxib-drugs, a process for preparing the said pharmaceutical composition and its use.It has been founded in this invention that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can afford a pharmaceutical composition which can prevent from decreasing the blood exposure, AUC and bioavailability. The pharmaceutical composition of the present invention has also good stability, which is useful for drugs. Namely, the technological thought that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can prevent from decreasing the blood exposure, AUC and bioavailability has been established in this invention.
摘要翻译：在本发明中已经建立，向第三代柯西班药物中加入碱性胺或碱性氨基酸或环糊精可以提供可以防止降低血液暴露AUC和生物利用度的药物组合物。本发明的药物组合物也具有良好的稳定性，对药物有用。也就是说，在本发明中已经建立了向第三代柯西班药加入碱性胺或碱性氨基酸或环糊精的技术思想可以防止血液暴露降低，AUC和生物利用度。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式